Arbele Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 17

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $10M

  • Investors
  • 4

Arbele General Information

Description

Operator of a biotechnology and biopharmaceutical company intended to develop advanced cancer therapies, including immunotherapies, multispecific antibody platforms, and targeted drug conjugates, with emphasis on gastrointestinal and solid-tumor cancers. The company offers advanced data analysis capabilities to cure GI cancers (colon, stomach, pancreas, liver, and esophagus) for the development of targeted therapies that improve patient outcomes and quality of life, enabling businesses to identify anomalies, bugs, and malicious events, enhancing operational efficiency.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 12011 Bel-Red Road
  • Suite 201
  • Bellevue, WA 98005
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 12011 Bel-Red Road
  • Suite 201
  • Bellevue, WA 98005
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arbele Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) $10M Completed Clinical Trials - Phase 1
3. Accelerator/Incubator 04-Dec-2022 Completed Clinical Trials - Phase 1
2. Grant 07-Apr-2021 $3M $129K Completed Clinical Trials - Phase 1
1. Accelerator/Incubator 01-Jan-2021 $129K $129K Completed Clinical Trials - Phase 1
To view Arbele’s complete valuation and funding history, request access »

Arbele Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology and biopharmaceutical company intended to develop advanced cancer therapies, including immun
Drug Discovery
Bellevue, WA
17 As of 2026

Culver City, CA
 

Carlton, Australia
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Arbele Competitors (4)

One of Arbele’s 4 competitors is TORL BioTherapeutics, a Venture Capital-Backed company based in Culver City, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
TORL BioTherapeutics Venture Capital-Backed Culver City, CA
Chimeric Therapeutics Formerly VC-backed Carlton, Australia
Simcere Private Equity-Backed Nanjing, China
Boehringer Ingelheim Corporation Ingelheim Am Rhein, Germany
To view Arbele’s complete competitors history, request access »

Arbele Patents

Arbele Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026060187-A1 Multispecific antibody-drug conjugates (adc) targeting cdh17-expressing tumors and method of making and using thereof Pending 11-Sep-2024
US-20260309708-A1 Compositions and methods for determining the effects of t cell engager Pending 17-Apr-2023
WO-2024220437-A2 Compositions and methods for determining the effects of t cell engager Inactive 17-Apr-2023
WO-2024220437-A3 Compositions and methods for determining the effects of t cell engager Inactive 17-Apr-2023
US-20250034273-A1 Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof Inactive 08-Oct-2021 C07K16/30
To view Arbele’s complete patent history, request access »

Arbele Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arbele Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hong Kong Science & Technology Parks Accelerator/Incubator Minority
AFCR Not-For-Profit Venture Capital
HK Tech 300 Accelerator/Incubator Minority
AIM-HI Accelerator/Incubator Minority
To view Arbele’s complete investors history, request access »

Arbele Investments (2)

Arbele’s most recent deal was a Joint Venture with Celvita. The deal was made on 09-Feb-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Celvita 09-Feb-2023 Joint Venture Other Healthcare Services
Cellular Immunotherapy (Arbele/Avalon GloboCare) 23-Oct-2018 Joint Venture Drug Discovery
To view Arbele’s complete investments history, request access »

Arbele FAQs

  • When was Arbele founded?

    Arbele was founded in 2016.

  • Where is Arbele headquartered?

    Arbele is headquartered in Bellevue, WA.

  • What is the size of Arbele?

    Arbele has 17 total employees.

  • What industry is Arbele in?

    Arbele’s primary industry is Drug Discovery.

  • Is Arbele a private or public company?

    Arbele is a Private company.

  • What is Arbele’s current revenue?

    The current revenue for Arbele is .

  • How much funding has Arbele raised over time?

    Arbele has raised $11.2M.

  • Who are Arbele’s investors?

    Hong Kong Science & Technology Parks, AFCR, HK Tech 300, and AIM-HI have invested in Arbele.

  • Who are Arbele’s competitors?

    TORL BioTherapeutics, Chimeric Therapeutics, Simcere, and Boehringer Ingelheim are competitors of Arbele.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process